Protective Effect of L-Arginine and Filgrastim Against Valproic Acid-Induced Histopathological Changes on the Gastric
Salwa M Ouies1, Yahia A Amin2, Noha A Ragab1
1Department of Human Anatomy and Embryology, Faculty of Medicine, Sohag University, Sohag, Egypt.
Abstract:
Valproic acid (VPA) is a commonly used anticonvulsant prescribed for various neurological disorders. Adverse effects may arise from chronic use and high dosages. This study aims to evaluate the protective effects of L-arginine and Filgrastim against the harmful impact of VPA on gastric and lingual mucosa. Forty male albino rats were divided into four groups (10 for each). The control group received saline, while the VPA group administered VPA (500 mg/kg) orally for 14 days. The VPA + L-arginine and VPA + Filgrastim groups received L-arginine (300 mg/kg) and Filgrastim (40 μg/kg), respectively, starting 3 days prior to VPA administration and continued concurrently with VPA for 14 days. Results revealed that VPA caused a decrease in gastric and lingual malondialdehyde (MDA) and superoxide dismutase (SOD) levels, tissue damage, and ulceration in the gastric mucosa. Lingual papillae appeared atrophied. A significant reduction in gastric mucosal thickness, parietal cell number, and fungiform papillae height was found, while the fungiform papillae width was significantly increased. Increased caspase-3 reaction in the parietal and chief cells of the gastric mucosa, as well as in the filiform and fungiform papillae of the tongue, was observed. The VPA + L-arginine and VPA + Filgrastim groups showed improvement in gastric and tongue biochemical and histological abnormalities, with a marked decrease in the caspase-3 reaction in gastric tissue. In the VPA + Filgrastim group, only the tongue tissue showed decreased caspase-3 reaction. It can be concluded that L-arginine and Filgrastim demonstrated effective protection of gastric and lingual mucosa against VPA-induced damage.
Related Concept Videos
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Gastritis-II: Pathophysiology
In acute gastritis, the gastric mucosa becomes swollen and red and undergoes superficial erosion. Superficial ulceration may lead to bleeding.
In chronic gastritis, persistent or repeated insults lead to chronic inflammatory changes and, eventually, thinning or atrophy of the gastric tissue.
Gastritis can stem from various causes, each...
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors
Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists
Pathophysiology of Peptic Ulcer Disease: Injurious Factors
In the antrum region, G cells secrete the gastrin hormone that binds to gastrin-cholecystokinin-B (CCK2) receptors on parietal and enterochromaffin-like (ECL) cells in the fundic glands. Simultaneously, the vagus nerve releases acetylcholine, which binds...


